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2008 Headline: “Data exclusivity recognizes the substantial investment that 
innovators must make to develop the safety and efficacy data necessary to gain 
FDA regulatory approval.”1 
2019 Headline: Artificial intelligence and biomarkers change drug discovery, 
making it more efficient and less risky. 
Machine learning and other technologies are expected to make the hunt for 
new pharmaceuticals quicker, cheaper and more effective.2 
Given that technological advancement reduces the cost and the time for drug 
discovery and approval, the authors raise the issue of whether we still need the 12-
years of exclusivity3 that was needed in 2008? 
 
* Jonathan Kimball is a Vice President for Trade and International Affairs at the Association for Accessible 
Medicines.  Srividhya Ragavan is a Professor of Law at Texas A&M School of Law; Sofia Vegas is a senior at 
Georgetown University and was an intern at the Association for Accessible Medicines when she worked on this 
paper.  
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One of the trickiest issues with drug development has been the balancing of 
costs and associated risks with the pricing of a drug. A good balance of these 
factors is essential to arrive at a price that incentivizes research without 
compromising on affordability of the medication. To compensate for the cost and 
risk associated with drug development, pharmaceutical companies enjoy 
government protections which allow them to maintain a monopoly over their 
products for an extended period of time. But, the balance between pricing and 
access has become so skewed in favor of the drug companies that the never-ending 
increasing costs of new life-saving medications raise questions about the basic 
assumptions on which the government built protections for the industry. 
Governments provide data or market exclusivity to incentivize innovation. 
While in theory, the exclusivity period is commensurate with the expense of 
bringing a drug to the market, the cost of that research and development process 
remains a disputed factor. On the one hand, drug development is estimated to be a 
whopping $2.7 billion, while others academic studies suggest  at a more 
manageable $648 million.4 It is also estimated that it takes at least six to seven 
years to go from initial discovery to the marketplace, wherein drugs undergo 
extensive clinical trials.5  Given this, the term of exclusivity—whether it be patent, 
data or market exclusivity—is structured to allow pharmaceutical companies to 
keep follow-on producers away from the market for a limited period of time. But, 
it is sometimes critical for follow-on producers to access this proprietary data in 
order to enter the market as soon as the period of patent exclusivity ends. For 
example, for small molecule drugs, the proprietary data developed by the original 
medicine producer is important for follow-on producers to file generic 
applications. 
This paper focuses on the assumptions used to justify the current terms of data 
and market exclusivity. It is important to appreciate that the term of exclusivity 
does not change to accommodate varying periods of drug development. Such set 
terms do not recognize that drug development is not a stagnant science. Rather, it 
is a dynamic process that builds off gained knowledge and technological 
advancements and leads to innovations both significant and minor. 
 
557 NATURE S55, S55 (May 31, 2018) (on file with The University of the Pacific Law Review) (defining the term 
market exclusivity). The Flemings article makes the distinction as appropriate and highlights the distinctions 
where required. 
4. Costs to Bring a Drug to Market Remain in Dispute, MANAGED CARE (Sept. 14, 2017), 
https://www.managedcaremag.com/news/20170914/costs-bring-drug-market-remain-dispute (on file with The 
University of the Pacific Law Review). 
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Meanwhile, new and emerging technologies are being used to enhance 
efficiencies and reduce the time it takes to bring a drug to the market.  As a result, 
pharmaceutical companies are able to not only launch products sooner but also run 
clinical trials more quickly and with less cost. Considering this, the Article asserts 
that as new technologies are adopted and advances in scientific understanding are 
leveraged resulting in shorter drug development timelines, it will be important to 
reduce the period of exclusivity granted to small molecule drugs and biologics. 
After discussing the nature of pharmaceutical exclusivity, this Article 
highlights key technological changes and how those changes impact 
pharmaceutical research and development. Lastly, the Article discusses how both 
cost and efficiencies are improved from the use of technology, thus making the 
case for reducing the time period for protection of data exclusivity. 
II. THE NATURE OF PHARMACEUTICAL EXCLUSIVITY 
Pharmaceutical exclusivity is a period of protection—sometimes described as 
“market exclusivity” or “data exclusivity” depending on the scope and effect of 
the particular type of exclusivity granted by governments to pharmaceutical 
companies that results in delayed competition. The objective of this protection 
period is to compensate companies for the costs and risks associated with clinical 
trials and drug development. The term “data exclusivity” refers to statutory 
provisions that protect clinical trial data such that it results in prohibition of 
reliance on the submitted data towards approval or submission of abbreviated 
applications for generic versions of brand-name drug products. “Market 
exclusivity,” a different type of protection, is the period when the regulatory body 
accepts applications for follow-on products, but does not grant approval, per se, 
which results in ensuring additional monopoly protections. Thus, data exclusivity 
essentially treats the data generated during clinical trials submitted to the United 
States Food and Drug Administration (“FDA”) towards marketing approval 
agencies as exclusive to the organization/corporation that conducted the clinical 
trial; market exclusivity ensures that the original producer faces no competition 
from a follow-on product. 
Operationally, the data exclusivity regime provides a layer of protection for 
the data gathered by innovator drug companies and operates outside the realm of 
patent protection. For innovator pharmaceuticals, protecting the clinical trial data 
provides an additional economic opportunity by creating a new market for the 
information relating to safety and efficacy of the drug. Such exclusivity may 
operationally help provide market exclusivity for compound(s) that may even fail 
patent scrutiny. 
Currently, taking small molecule drugs as an example, the protection is for the 
data that the organization developed during the research process. This form of 
protection does not exclude generic competition de jure, presuming there is no 
active patent protection.  However, it does provide de facto monopoly conditions, 
since there are very few instances when the company producing the follow-on 
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product would choose to make the investment in clinical trials necessary to prove 
safety and efficacy. For the follow-on generic company, the preference would be 
to just wait until the data exclusivity period expires. Unlike patent protection, the 
period of data exclusivity is linked directly to the data of marketing approval. 
Entering the market after the expiration of data exclusivity is cost effective for the 
generic drug companies since, by not undertaking their own clinical research, 
generic drug companies are able to price their products more competitively. 
For biologics, which are increasingly important (and expensive) options for 
patients living with cancer, autoimmune and other maladies, the exclusivity period 
is not only longer (12 vs. 5-7.5 years in the United States), but also provides a 
guaranteed market exclusivity period extending to 12 years. During the first four 
years of the 12-year period, the original reference brand product has both data 
exclusivity and market exclusivity, based on the pathway described in Section 
351(k) of the Public Health Services Act.6 Specifically, data exclusivity is provided 
to the original biologic drug for four years, during which time the FDA cannot 
accept an application for a biosimilar product referencing that original product. 
Following the end of that four-year period and for an additional eight years, a 
biosimilar manufacturer can submit a marketing authorization application, but the 
FDA cannot approve that application, resulting in a combined 12 years of market 
exclusivity for the original biologic product.7 
Duke University professor Henry G. Grabowski had defended—and continues 
to defend8—the 12-year exclusivity period for biologics.9 His study, published in 
2008 with data from 2006 and earlier,(and paid for by the Pharmaceutical Research 
and Manufactures of America (“PhRMA”)), found that “break-even lifetime for 
the portfolio occurs at 12.9 years . . .. This sensitivity reflects the lengthy research 
and development (“R&D”) investment periods associated with pharmaceutical and 
biopharmaceutical investments.”10 Professor Grabowski takes the example of 
bevacizumab (Avastin; Genentech/Roche), which is one of the first of a new class 
of drugs to treat colorectal cancer. The paper illustrates that in 1997, Genentech 
submitted information on bevacizumab, a workable antibody, to the FDA. 
Although Phase I of the clinical trials commenced the same year, the trial finally 
6. See  42 U.S.C. § 262(k) (2017); Catherine Garza, Effects on Exclusivity: The Biologics Price Competition
and Innovation Act of 2009, CAMARGO (Sept. 1, 2016), available at 
https://camargopharma.com/resources/blog/effects-on-exclusivity-the-biologics-price-competition-and-
innovation-act-of-2009 (on file with The University of the Pacific Law Review). 
7. See 42 U.S.C. § 262(k) (2017).
8. Stephen Ezell et al., US Must Stand Up For Life-Sciences Innovation Provisions in the USMCA, HILL
(June 6, 2019, 1:30 PM), available at https://thehill.com/opinion/international/447247-us-must-stand-up-for-life-
sciences-innovation-provisions-in-the-usmca (on file with The University of the Pacific Law Review).  
9. Henri Grabowski, Follow-On Biologics: Data Exclusivity and the Balance Between Innovation and
Competition, 7 NATURE REVS. DRUG DISCOVERY 479, 479 (June 2008), https://www.nature.com/articles/nrd2532 
(on file with The University of the Pacific Law Review).  
10. Stephen Ezell et al., US Must Stand Up For Life-Sciences Innovation Provisions in the USMCA, HILL
(June 6, 2019, 1:30 PM), available at https://thehill.com/opinion/international/447247-us-must-stand-up-for-life-
sciences-innovation-provisions-in-the-usmca (on file with The University of the Pacific Law Review). 
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ended in February 2004, allowing the FDA to approve bevacizumab as the first 
anti-angiogenic drug for treating cancer. While confirming that biologics overall 
had a better success rate than chemicals for approval, the study focuses on failure 
rates and probabilities of success as opposed to actual rates of success to arrive at 
the 12.9 years of exclusivity. Since its publication, this study has raised questions 
repeatedly, with critics challenging its premise that 12 years is necessary to 
incentivize the development of biosimilars.11 In fact, just recently, Nature 
Biotechnology found that “preclinical development times were not different 
between biologic and small-molecule drugs but were shorter for biologics.”12 
The Grabowski argument is sometimes justified on the grounds that patents on 
biologics are not always granted and often are more susceptible to being 
invalidated. Hence, the wisdom is to bestow drug companies inordinate periods of 
exclusivity so they would not be discouraged from investing in research over 
biological substances. Others assert that “biotech products, like monoclonal 
antibodies, are very difficult for generic companies to develop and the absence of 
data exclusivity in a country would discourage the originator company from 
entering this market, which would have the deleterious effect of depriving people 
of the benefits of these drugs.”13 Nevertheless, even Professor Grabowski 
highlights a red-flag that can potentially choke competition in adding that, “if data 
exclusivity periods are too long, price competition could be delayed beyond what 
is necessary to encourage innovation.”14 
Two important changes comport with the red flags that Professor Grabowski 
raises and consequently, makes his analysis dated. First, new technology such as 
AI has contributed to shortening the time required for clinical trial such that the 
long period of exclusivity is not justified. Second, pharmaceutical companies have 
tended to seek additional periods of exclusivity such as through orphan designation 
or, pediatric exclusivity.15 For example, in the United States, in addition to the data 
and market exclusivity period awarded for NCEs, a pediatric exclusivity of 6 
months,16 which is a form of market exclusivity for the pediatric designation is 
 
11. Zachary Brennan, New Study Questions the Need for 12 Years of Market Exclusivity for Biologics, 
REGULATORY FOCUS (June 21, 2019), available at https://www.raps.org/news-and-articles/news-
articles/2019/6/new-study-questions-the-need-for-12-years-of-marke (on file with The University of the Pacific 
Law Review). 
12. Reed F. Beall et al., Pre-Market Development Times for Biologic Versus Small-Molecule Drugs, 37 
NATURE BIOTECHNOLOGY 708, 709 (June 18, 2019), available at https://www.nature.com/articles/s41587-019-
0175-2.pdf (on file with The University of the Pacific Law Review). 
13. Wael Armouti & Mohammad F.A. Nsour, Data Exclusivity for Pharmaceuticals: Was It 
the Best Choice for Jordan Under the U.S.- Jordan Free Trade Agreement?, 17 OREGON REV. INT’L L. 258, 260 
(2016), available at https://law.uoregon.edu/images/uploads/entries/Nsour.pdf (on file with The University of the 
Pacific Law Review). 
14. Henri Grabowski, Follow-On Biologics: Data Exclusivity and the Balance Between Innovation and 
Competition, 7 NATURE REVS. DRUG DISCOVERY 479, 479 (June 2008), https://www.nature.com/articles/nrd2532 
(on file with The University of the Pacific Law Review).  
15. See Federal Food, Drug, and Cosmetic (FD&C) Act of 1938 § 505(a), 21 U.S.C. § 355(a) (2012) 
(granting an additional 6-month period of exclusivity  to the existing 12- and 4- year exclusivity periods). 
16. See Federal Food, Drug, and Cosmetic (FD&C) Act of 1938 § 505(a), 21 U.S.C. § 355(a) (2012) 
2020 / Reconsidering the Rationale for the Duration of Data Exclusivity 
530 
added to some existing drugs. This extension attaches at the end of term if the 
sponsor submits pediatric studies on the active moiety in response to a Written 
Request from  FDA. 
The real world experience of biologic producers demonstrates that exclusivity 
for biologics can be much longer than even the 12.9 years that Grabowski 
suggested. For an increasing number of approved biologics, a separate period of 7 
years of exclusivity may be awarded under the Orphan Drugs Act for each use of 
the drug to treat an orphan condition.17 For the orphan indication, a biosimilar 
(section 351(k) of Public Health Services Act) product may not be licensed by the 
FDA until after the expiration of the 7-year orphan drug exclusivity period or the 
12-year reference product exclusivity, whichever is later. Thus, if the product with 
a 12-year exclusivity gets approval for an orphan indication in its, say, 11th year, 
the biosimilar will benefit from 17 years of different forms of hybrid 
exclusivities.18 Recently, National Public Radio reported that more than 70 drugs) 
that were approved as Orphan Drugs were in fact familiar brand names which were 
strategically later approved as orphans - out of the 148 records the Government 
Accountability Office reviewed, 38.5% had been previously approved drugs.19 
Such examples include popular mass market drugs, such as the cholesterol 
blockbuster Crestor, Abilify for psychiatric conditions, cancer drug Herceptin, and 
rheumatoid arthritis drug Humira, which is the best-selling medicine in the world 
(earning more than $19 billion in 2018 alone).20 Each of these represent the re-
approval of a mass marketed drug as an orphan drug when their patent was about 
to expire. In essence, the orphan status essentially enabled an additional seven 
years of exclusivity for a drug which already benefitted from patent protection as 
well as one layer of data and market exclusivity for treating another disease. This 
phenomenon is the red-flag that Grabowski himself highlighted, making a case for 
reduced term of protection. 
Second, the use of artificial intelligence, biomarkers, patient-centered mobile 
technology, and other medical and technological advancements has improved drug 
candidate identification, patient participation in and engagement during clinical 
trials, and the overall likelihood of trial success. For example, in oncology, 
advanced analytics and the increased use of biomarkers have improved the ability 
to identify unique gene signatures and support the identification of clinical trial 
 
(granting an additional 6-month period of exclusivity  to the existing 12- and 4- year exclusivity periods). 
17. FD&C Act § 527(a).  
18. FD&C Act § 527(a). Andrew Bourgoin & Beth Nuskey, An Outlook on US Biosimilar Competition – 
White Paper, Thomson Reuters (April 2013), https://healthtrustpg.com/biosimilars/pdf/thomson-reuters.pdf. 
19. Sarah J. Tribble, GAO Will Investigate Skyrocketing Prices For Orphan Drugs, NPR, March 22, 2017 
https://www.npr.org/sections/health-shots/2017/03/22/521081742/gao-will-investigate-skyrocketing-prices-for-
orphan-drugs; see also Sarah J. Tribble & Sydney Lupkin, FDA Faulted for Lapses in Orphan Drug Program, 
NPR (Nov. 30, 2018), https://www.npr.org/sections/health-shots/2018/11/30/672287029/fda-faulted-for-lapses-
in-orphan-drug-program (on file with The University of the Pacific Law Review). 
20. AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results, ABBVIE (Jan. 25, 2019), 
available at https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2018-financial-
results.htm (on file with The University of the Pacific Law Review).  
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participants at a faster rate and with greater precisions than previously. 
Considering these developments, IQVIA’s Clinical Trial Trends Impact 
Assessment tool suggests that there will be a 104% and 71% increase in oncology 
R&D productivity because of advanced analytics and biomarkers, respectively.21 
Technological advancements such as these promise to significantly reduce the 
time between initial research and regulatory approval, increase the likelihood of 
trial success, while also reducing the cost of such trials. In doing so, they defy the 
logic behind the Grabowski analysis based on which the current terms of 
exclusivity are structured. That is, as these technologies are increasingly used in 
biopharmaceutical R&D, the need for long periods of exclusivity is reduced. In 
fact, as technology advances and continues to increase efficiencies in drug 
development, the case for lengthy exclusivity periods weakens considerably. 
III. TECHNOLOGICAL ADVANCES 
This section identifies several technological advances that hold the promise of 
significantly reducing the time and risk involved in drug development. 
Specifically, we examine the impact of artificial intelligence, the increased use of 
biomarkers, and the growth in the use of patient centric mobile technology in 
clinical trials on drug development. 
A. Artificial Intelligence 
Artificial Intelligence can be used in multiple stages of the drug development 
process to reduce risk and minimize development time. First, AI can be used to 
analyze data to predict relationships between biological mechanisms and 
symptoms which can be useful for treatment, typifying and classifying patients, 
and for understanding side-effects. Second, AI can be immensely useful in the drug 
discovery stage. The IQVIA study mentions that, “when applied in the discovery 
field, AI may strengthen computational models that predict link between drug 
structure and activity/efficacy/safety (i.e. SAR) to improve success rates.”22 AI’s 
ability to generate benefits has resulted in collaborative models that vastly improve 
the involved processes. For instance, Michael Devoy, the Chief Medical Officer of 
Bayer AG’s Pharmaceutical Division noted that, “we are in active collaborations 
in the Cardiovascular and Oncology therapeutic areas with external partners (e.g., 
the BROAD institute) to achieve [better characterize and stratify disease and the 
 
21. IQVIA INST. FOR HUM. DATA SCI., THE CHANGING LANDSCAPE OF RESEARCH AND DEVELOPMENT: 
INNOVATION, DRIVERS OF CHANGE, AND EVOLUTION OF CLINICAL TRIAL PRODUCTIVITY, 4 (Apr. 2019), 
available at https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-
research-and-development.pdf (on file with The University of the Pacific Law Review).  
22. IQVIA INST. FOR HUM. DATA SCI., THE CHANGING LANDSCAPE OF RESEARCH AND DEVELOPMENT: 
INNOVATION, DRIVERS OF CHANGE, AND EVOLUTION OF CLINICAL TRIAL PRODUCTIVITY, 43, 58 (Apr. 2019), 
https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-research-and-
development.pdf (on file with The University of the Pacific Law Review). 
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appropriate patient solutions].”23 This type of cooperation is especially important 
in the early phase of drug discovery. 
Once a drug is developed, AI helps improve and quicken the ability of drug 
companies to analyze the wealth of data. This includes data already created in past 
clinical trials, as well as new data that is being compiled internally by the company 
and externally through partners such as universities, government research 
institutes, and biobanks. In this arena, AI will lead to better and faster analysis of 
available data, generating new hypotheses to test clinically, speeding the 
enrollment by guiding patient identification, enabling precision to better detect 
treatment effectiveness, predicting which clinical sites are most likely to recruit 
and perform well, and enabling novel trial designs including adaptive trials.24 
IQVIA, through its Clinical Development Productivity Index, predicts the 
percent change in clinical productivity driven by AI and predictive analytics to be 
16% in 5 years.25 In turn, the expedited analysis will lead to the next benefit of 
using AI, which is accuracy. By allowing for candidates of specific drugs to be 
more accurately identified, AI can also decrease the time and cost of drug 
development and thus, improve efficiency. Merck KGaA’s website substantiates 
this in stating that, “artificial intelligence is emerging as a pillar in the 
biopharmaceutical R&D model, giving us exponential opportunity to complement 
our existing expertise with further speed and better precision. For patients, this 
could mean faster access to novel treatment options.”26 
AI has already proven to be more efficient in the scientific realm. DeepMind, 
a company of Google’s parent company Alphabet Inc., uses AI for different types 
of scientific discovery. In 2018, DeepMind competed against scientists with high 
levels of expertise in drug development and proved itself more successful at 
predicting 3D structures of proteins in the CASP13 competition with its AI 
invention, AlphaFold. Accurate modeling of protein structures could speed up drug 
development. AlphaFold was able to determine the proteins with higher accuracy 
and faster pace the majority of the time when compared to highly experienced drug 
researchers. Evidently, as shown by DeepMind, AI has the potential to expedite 
 
23. Michael Devoy, Artificial Intelligence: Technology Driven Prediction to Advance Patient Care, 
PHARMA.BAYER (Aug. 3, 2019), available at http://pharma.bayer.com/en/innovation-partnering/artificial-
intelligence-technology-driven-disease-prediction-to-advance-patient-care/ (on file with The University of the 
Pacific Law Review). 
24. IQVIA INST. FOR HUM. DATA SCI., THE CHANGING LANDSCAPE OF RESEARCH AND DEVELOPMENT: 
INNOVATION, DRIVERS OF CHANGE, AND EVOLUTION OF CLINICAL TRIAL PRODUCTIVITY, 5 (Apr. 2019), 
available at https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-
research-and-development.pdf (on file with The University of the Pacific Law Review). 
25. IQVIA INST. FOR HUM. DATA SCI., THE CHANGING LANDSCAPE OF RESEARCH AND DEVELOPMENT: 
INNOVATION, DRIVERS OF CHANGE, AND EVOLUTION OF CLINICAL TRIAL PRODUCTIVITY, 43, 58 (Apr. 2019), 
available at https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-
research-and-development.pdf (on file with The University of the Pacific Law Review). 
26. Merck KGaA, Darmstadt, Germany, Announces Collaboration with Iktos for Generative Artificial 
Intelligence (AI) Technology, EMDGROUP (Mar. 14, 2019), https://www.emdgroup.com/en/news/collaboration-
with-iktos-14-03-2019.html (on file with The University of the Pacific Law Review). 
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and decrease the cost of drug development. For this reason, the success of 
AlphaFold’s new AI machine brings high expectations to the future of drug 
development.27 
In sum, almost all major pharma companies have significant projects with AI 
companies, as most recognize the role that AI can play in drug development. 
BenchSci reports that at least 33 pharmaceutical companies are engaged in AI.28 
Also, most are looking to stay ahead of the game and perfect their drug 
development process. 
B. Biomarker Identification 
Biomarkers are also changing the way drugs are developed and how they reach 
the market. A biomarker is “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.”29 Biomarkers in clinical 
studies have been used for diagnosis and as “a tool for staging disease as indicators 
of disease status, and to predict and/or monitor clinical response to therapeutic 
intervention (e.g., electrocardiogram, PET brain image, serum chemistries, auto-
antigens n blood, bone densitometric measurement, pulmonary function test, 
neonatal Apgar score).”30 If used effectively, drug developers will be able to gain 
more insight into biomarkers themselves. This, in turn, will undoubtedly increase 
the probability of successful use of biomarkers for more accurate drug 
development and higher beneficial outcomes for patients. 
As biomarkers become a staple of drug development and usage, the time it 
takes to create a drug will decrease, bringing down its costs as well. As noted by 
IQVIA, “[b]iomarkers will have the greatest impact on clinical productivity 
yielding a 34% average increase [in productivity] across all phases of 
development.”31 This is because during clinical development, biomarkers will alter 
patient eligibility criteria to a narrower population and decrease sample size, “add 
 
27. Jeremy Kahn, Alphabet’s DeepMind AI Algorithm Wins Protein-Folding Contest, BLOOMBERG (Dec. 
2, 2018, 7:36 PM), https://www.bloomberg.com/news/articles/2018-12-03/alphabet-s-deepmind-ai-algorithm-
wins-protein-folding-contest (on file with The University of the Pacific Law Review).  
28. Simon Smith, 33 Pharma Companies Using Artificial Intelligence in Drug Discovery, BENCHSCI. (Sept. 
3, 2019), available at https://blog.benchsci.com/pharma-companies-using-artificial-intelligence-in-drug-
discovery (on file with The University of the Pacific Law Review). 
29. See JK Aronson et al., Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual 
Framework, NIH Biomarkers Definitions Working Group, 1998, BR J CLIN PHARMACOL 2005 May; 59(5): 491– 
94, 491 (2005), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884846/ (on file with The 
University of the Pacific Law Review). 
30. Attila A. Seyhan, Biomarkers in Drug Discovery and Development, EUR. PHARM. REV. (Nov. 1, 2010), 
https://www.europeanpharmaceuticalreview.com/article/4357/biomarkers-drug-discovery-development/ (on file 
with The University of the Pacific Law Review). 
31. IQVIA INST. FOR HUM. DATA SCI., THE CHANGING LANDSCAPE OF RESEARCH AND DEVELOPMENT: 
INNOVATION, DRIVERS OF CHANGE, AND EVOLUTION OF CLINICAL TRIAL PRODUCTIVITY, 58 (Apr. 2019), 
available at https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-
research-and-development.pdf (on file with The University of the Pacific Law Review). 
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new dimensions of genomic data access to trial recruitment,” “strengthen drug 
efficacy signals and reduce side effects,” “enable novel trials designs including 
basket trial designs,” and “enable a shift to more standardized efficacy and safety 
endpoints among biomarkers related to therapeutic response.”32 The ability to 
target specific populations decreases the risk of drug development including the 
challenge of patient recruitment for trials. If this is the case, the drug development 
period will undoubtedly decrease, proving it no longer necessary to have such 
elevated exclusivities. 
Biomarkers will allow pharmaceutical companies to work specifically on a 
patient-by-patient basis in order to determine drug prescriptions. As found by 
Attila Seyhan, “effective translation of the preclinical biomarkers into the clinic 
will pave the way towards effective execution of personalized therapies across 
complex disease areas for the benefit of patients, healthcare providers and the bio-
pharmaceutical industry.”33 The increased use of biomarkers will help identify 
subgroups of patients susceptible to specific sub-variants of diseases and specific 
populations that will benefit from specific therapies. 
C. Patient-centered Mobile Technology 
The use of mobile technology by patients in clinical trials will also be 
beneficial for drug development. This technology allows increased feedback on a 
range of inputs that will help identify benefits and risks of a therapy as it moves 
through the development process, including in phase IV trials. This type of 
technological advancement is leading to better care for patients. Not only this, but 
it has also proven to be a great source of real-world data collection. The wealth of 
data that can be collected remotely and continuously also allows for increased use 
of adaptive trial design, increasing the potential for trial success. 
Digital health and mobile technologies centered in patient input will “improve 
the capture of drug efficacy and safety data,” “facilitate the collection of patient-
reported outcomes,” “improve patient safety within a trial setting,” “enable virtual 
patient visits and site-less trial formats,” “improving patient experience,” and 
“reduce trial management ‘work burden’ at clinical site and speed recruitment.”34 
This will be facilitated by tools such as telemedicine and virtual physician visits, 
connected biometric sensors, consumer mobile apps, disease management apps, 
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consumer wearables, in-home connected virtual assessments, and web-based 
interactive programs. 
Different uses of patient-centric technology will benefit the drug development 
process. As mentioned by Ronak Savla, scientific affairs manager at Catalent 
Pharma Solutions, “whilst the need for patient centricity has always existed, the 
focus on it has never been greater. Every dose design decision during development 
has the potential to influence patient outcomes. Besides safety and efficacy, 
patient-centricity should be the foundation of creating target product profile.”35 As 
pharmaceutical producers continue to integrate patient-centered technology in 
their drug development, the efficiency and accuracy of medicines will 
exponentially grow. 
The IQVIA Clinical Development Productivity Index found that patient-
centered mobile technologies and the real-world data they help capture will have 
a 13% and 12% clinical productivity increase, respectively.36 This technology will 
also be beneficial for the later stages of development and drug approval. As stated 
by PhRMA, “advancing science-based approaches to collect robust and 
meaningful patient and caregiver input can more consistently inform drug 
development and regulatory decision making.”37 The continued advancement of 
this type of care, will decrease drug development time and increase its accuracy 
and quality, thus pointing, once again, to the inefficiency of elevated exclusivity 
periods. 
IV. TECHNOLOGICAL ADVANCEMENT & IMPACT OF EXCLUSIVITY DURATION 
From manufacturing to services to research and development, artificial 
intelligence, mobile technology, expansive scientific understanding, and other 
technologic advances have created economic efficiencies that drive down both the 
cost and the time it takes to develop a wide range of new consumer and industrial 
products. Biopharmaceutical research and development is no different. 
Technological advancements are becoming a game changer for drug development. 
As the above discussion highlights, they are creating an environment for more 
efficient research and development, with a reduction in both risk and development 
times. 
Technology helps by better predicting the likelihood of toxicity in the earliest 
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stages before a company even tries to take a drug to clinical trials. That would 
directly save the company money and time. For example, Pfizer collaborates with 
IBM to use Watson for drug discovery. IBM points out the average human 
researcher reads between 200 and 300 science articles a year while Watson has 
“ingested 25 million Medline abstracts, more than 1 million full-text medical 
journal articles, 4 million patents and is regularly updated.”38 The depth of 
knowledge that is created in such a short time can possibly enable machines to 
determine non-obvious connections that could lead to combination medicines for 
cancer.39 Similarly, Andrew Hopkins, the CEO of Exscientia, noted that, compared 
to traditional methods, Exscientia’s system can deliver drug candidates roughly 25 
percent faster and 25 percent cheaper. The algorithms can design new molecules 
and is intended to be able to better predict which molecules would be the most 
effective and safest.40 
The costs and efficiencies presented by these technological advances make the 
argument for 12 years in the Grabowski article outdated. The assumption that 12 
years of exclusivity will always be needed—or, as indicated in the Nature 
Biotechnology study noted above, is currently needed—is false and lacks basis. In 
fact, as new technologies are adopted into the drug discovery process, and their 
related efficiencies are captured, exclusivity periods should be reduced. It is time 
to recognize that pharmaceutical policies, designed to incentive drug development, 
must be dynamic, adapting to the pace and reduced risk that is drug development 
today. 
V. CONCLUSION 
The nature of drug development continues to evolve as technological 
advancements become more integrated into product development. The use of 
artificial intelligence, biomarkers and patient-centered mobile technology have 
proven and will continue to prove themselves successful in expediting the 
development of a single drug. Therefore, as pharmaceutical companies continue to 
integrate these into their development process, the time it will take them to develop 
new drugs will undoubtably decrease. The shorter development time will lead to 
less expensive medicines. This will mean that 12-year market exclusivity periods 
currently protecting biologics from competition will increasingly be less relevant 
for compensating for the time it takes to develop a drug. 
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As technological advances improve the success of drug development, and do 
so in less time than it has traditionally taken to develop a drug, the rationale for 
long periods of exclusivity will be decreased. Such a reduction will benefit 
healthcare systems, payers, patients, and, if it reflects increased certainty and less 
risk, the pharmaceutical industry as well. 
 
